Brief: Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz
05/06/2025 13:01
June 5 (Reuters) - Avadel Pharmaceuticals PLC AVDL.O: AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR LUMRYZ™ (SODIUM OXYBATE) FOR EXTENDED-RELEASE ORAL SUSPENSION FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA Source text: ID:nGNX8lGQVk Further company coverage: AVDL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avadel Pharmaceuticals
See all newsBrief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet